Replimune Group Inc (REPL)

$6.33 +0.52 (8.95%)
Market Cap 494.09M
Revenue (ttm) 0.00
Net Income (ttm) -247.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.14
Volume 3,714,900
Avg Vol 11,104,634
Day's Range N/A - N/A
Shares Out 78.06M
Stochastic %K 85%
Beta 0.51
Analysts Sell
Price Target $4.86

Company Profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express a...

Industry: Biotechnology
Sector: Healthcare
Phone: (781) 222-9600
Address:
500 Unicorn Park Drive, Suite 303, Woburn, United States
CC_Abbott
CC_Abbott Sep. 7 at 2:31 PM
$REPL If interested, Melanoma patients advocates' letter to the FDA https://www.aimatmelanoma.org/advocating-for-patients-letter-to-the-fda-on-rp1-treatment-access/
1 · Reply
MaxPower23
MaxPower23 Sep. 6 at 9:10 PM
$REPL Any take of someone whether CRL is same AI flawed bullshit as the one $CAPR received?
0 · Reply
BigGainTom
BigGainTom Sep. 5 at 8:53 PM
$REPL Big dump after hours
0 · Reply
Halbalidiya
Halbalidiya Sep. 5 at 7:09 PM
$REPL artificially held up so baker bros and jpm can dump slowly onto gullible retial.
1 · Reply
MrsBelfort
MrsBelfort Sep. 5 at 5:31 PM
$CAPR Probably a post that is 24 hours late but anyways: This was the CRL announcement from FDA: https://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89 They released an unpublished batch of 89! Even though AF's tweet says letters, he singled out CAPR and $REPL https://x.com/adamfeuerstein/status/1963615708236964114 I think the FUD being spread on there was that this was a direct response to Linda's comments from the day before. The shorts got what they wanted and the price dipped as low as $5.68 Note to Linda, beware of reporters. (AF, Bio reporter, etc.) These people are neither your friends nor your colleagues.
0 · Reply
Heroforest
Heroforest Sep. 5 at 4:08 PM
$CAPR so FDA will take hope 3 into consideration as the other study they required for approval… we are in a way better position than $REPL
0 · Reply
Ms_P
Ms_P Sep. 5 at 1:15 AM
$CAPR $REPL How long before Trump stops this nonsense? FDA approval less “guaranteed” than ever before. Doesn’t matter how many meetings the company has with FDA beforehand , doesn’t matter if they’re following what FDA wanted for study design. Frankly not seeing this change anytime soon under the new administration.
2 · Reply
bullbearcrab
bullbearcrab Sep. 4 at 8:13 PM
$REPL Seems kinda hopeless, I don't see them ever getting the accelerated approval and without it they are cooked. Surely the FDA won't put them back on the accelerated approval pathway just because they "talk it out" in the Type A meeting. FDA raised concerns regarding trial design, which they can't redo. There isn't any new data that they could cite either. Confirmatory phase 3 will not happen if accelerated approval doesn't. Don't mean to rain on the parade but if you are positive on the outcome of this Type A meeting, I'd love to hear counter arguments.
2 · Reply
Polip
Polip Sep. 4 at 4:10 PM
$IOVA I am reading the $REPL CRL letter. Pretty tough. New trial needed
3 · Reply
tttggg
tttggg Sep. 4 at 3:19 PM
$CAPR $REPL the CRLs are like Prasad’s declaration: look, I will not reverse the decisions!!
0 · Reply
Latest News on REPL
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Sep 6, 2025, 10:57 AM EDT - 1 day ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Sep 5, 2025, 6:54 PM EDT - 1 day ago

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Sep 2, 2025, 9:46 PM EDT - 4 days ago

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Replimune Announces Type A Meeting Scheduled with FDA

Sep 2, 2025, 8:00 AM EDT - 5 days ago

Replimune Announces Type A Meeting Scheduled with FDA

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Aug 28, 2025, 8:05 PM EDT - 9 days ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit – REPL

Aug 13, 2025, 4:39 PM EDT - 24 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit – REPL

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

Aug 13, 2025, 3:26 PM EDT - 24 days ago

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

Replimune Group: The Prospects For FDA Approval After Rejection

Aug 7, 2025, 10:08 AM EDT - 4 weeks ago

Replimune Group: The Prospects For FDA Approval After Rejection

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Aug 7, 2025, 8:00 AM EDT - 4 weeks ago

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Why Is Replimune Stock Trading Lower On Monday?

Aug 4, 2025, 12:43 PM EDT - 4 weeks ago

Why Is Replimune Stock Trading Lower On Monday?

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Aug 1, 2025, 10:51 AM EDT - 5 weeks ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

Jul 30, 2025, 8:36 AM EDT - 5 weeks ago

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Jul 28, 2025, 8:36 AM EDT - 5 weeks ago

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

Jul 25, 2025, 5:04 PM EDT - 6 weeks ago

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is Facing a Securities Fraud Investigation – Investors with Losses are Notified to Contact BFA Law

Jul 24, 2025, 8:07 AM EDT - 6 weeks ago

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is Facing a Securities Fraud Investigation – Investors with Losses are Notified to Contact BFA Law

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

Jul 22, 2025, 2:56 PM EDT - 6 weeks ago

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Jul 22, 2025, 11:03 AM EDT - 6 weeks ago

BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 11, 2025, 4:01 PM EDT - 2 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2025, 10:00 AM EDT - 3 months ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 3 months ago

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript

May 22, 2025, 11:19 AM EDT - 3 months ago

Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

May 22, 2025, 7:00 AM EDT - 3 months ago

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

May 16, 2025, 8:00 AM EDT - 4 months ago

Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025, 4:01 PM EDT - 4 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

May 8, 2025, 5:00 AM EDT - 4 months ago

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

COYA

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

Apr 28, 2025, 3:26 PM EDT - 4 months ago

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

Replimune: A Misunderstood Contender In Oncolytics

Feb 12, 2025, 4:21 PM EST - 7 months ago

Replimune: A Misunderstood Contender In Oncolytics

Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Feb 12, 2025, 8:00 AM EST - 7 months ago

Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2024, 8:00 AM EST - 9 months ago

Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch

Nov 29, 2024, 4:12 AM EST - 10 months ago

Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch

Replimune Announces Pricing of Upsized Public Offering

Nov 25, 2024, 11:55 PM EST - 10 months ago

Replimune Announces Pricing of Upsized Public Offering

Replimune Announces Proposed Public Offering

Nov 25, 2024, 7:09 AM EST - 10 months ago

Replimune Announces Proposed Public Offering

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Nov 21, 2024, 4:05 PM EST - 10 months ago

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

Nov 9, 2024, 1:00 PM EST - 10 months ago

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

CC_Abbott
CC_Abbott Sep. 7 at 2:31 PM
$REPL If interested, Melanoma patients advocates' letter to the FDA https://www.aimatmelanoma.org/advocating-for-patients-letter-to-the-fda-on-rp1-treatment-access/
1 · Reply
MaxPower23
MaxPower23 Sep. 6 at 9:10 PM
$REPL Any take of someone whether CRL is same AI flawed bullshit as the one $CAPR received?
0 · Reply
BigGainTom
BigGainTom Sep. 5 at 8:53 PM
$REPL Big dump after hours
0 · Reply
Halbalidiya
Halbalidiya Sep. 5 at 7:09 PM
$REPL artificially held up so baker bros and jpm can dump slowly onto gullible retial.
1 · Reply
MrsBelfort
MrsBelfort Sep. 5 at 5:31 PM
$CAPR Probably a post that is 24 hours late but anyways: This was the CRL announcement from FDA: https://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89 They released an unpublished batch of 89! Even though AF's tweet says letters, he singled out CAPR and $REPL https://x.com/adamfeuerstein/status/1963615708236964114 I think the FUD being spread on there was that this was a direct response to Linda's comments from the day before. The shorts got what they wanted and the price dipped as low as $5.68 Note to Linda, beware of reporters. (AF, Bio reporter, etc.) These people are neither your friends nor your colleagues.
0 · Reply
Heroforest
Heroforest Sep. 5 at 4:08 PM
$CAPR so FDA will take hope 3 into consideration as the other study they required for approval… we are in a way better position than $REPL
0 · Reply
Ms_P
Ms_P Sep. 5 at 1:15 AM
$CAPR $REPL How long before Trump stops this nonsense? FDA approval less “guaranteed” than ever before. Doesn’t matter how many meetings the company has with FDA beforehand , doesn’t matter if they’re following what FDA wanted for study design. Frankly not seeing this change anytime soon under the new administration.
2 · Reply
bullbearcrab
bullbearcrab Sep. 4 at 8:13 PM
$REPL Seems kinda hopeless, I don't see them ever getting the accelerated approval and without it they are cooked. Surely the FDA won't put them back on the accelerated approval pathway just because they "talk it out" in the Type A meeting. FDA raised concerns regarding trial design, which they can't redo. There isn't any new data that they could cite either. Confirmatory phase 3 will not happen if accelerated approval doesn't. Don't mean to rain on the parade but if you are positive on the outcome of this Type A meeting, I'd love to hear counter arguments.
2 · Reply
Polip
Polip Sep. 4 at 4:10 PM
$IOVA I am reading the $REPL CRL letter. Pretty tough. New trial needed
3 · Reply
tttggg
tttggg Sep. 4 at 3:19 PM
$CAPR $REPL the CRLs are like Prasad’s declaration: look, I will not reverse the decisions!!
0 · Reply
tttggg
tttggg Sep. 4 at 3:03 PM
$CAPR $REPL tbh I think the intention here is to justify the decision to turn down Repl & capr. Prasad is trying really really hard lol. Stubborn as usual.
0 · Reply
tttggg
tttggg Sep. 4 at 2:55 PM
$CAPR so the fda just published the CRLs to $REPL and capr to screw them over again???
0 · Reply
martinfpl86
martinfpl86 Sep. 4 at 2:05 PM
$REPL has another chance to present RP1 to the FDA. If approved, it could bring a much-needed treatment to advanced melanoma patients waiting for options. Still looks undervalued vs peers.
1 · Reply
Aphrodite_Lykaios
Aphrodite_Lykaios Sep. 4 at 2:05 PM
Biotech is always volatile, but I see $REPL as a survivor. The FDA meeting is a chance to reset the story and drive value.
0 · Reply
Longterm007
Longterm007 Sep. 4 at 10:34 AM
$REPL me 2
0 · Reply
ignoreo
ignoreo Sep. 4 at 5:42 AM
$REPL ill buy it back in the 2s
0 · Reply
Juba2022
Juba2022 Sep. 3 at 6:32 PM
$REPL News brewing!!!! I guess so.
0 · Reply
tradesprofit
tradesprofit Sep. 3 at 6:01 PM
$BA $REPL boom 200% 🟢
0 · Reply
The_Free_Trader
The_Free_Trader Sep. 3 at 2:53 PM
$REPL showing what happens when biotech risk isn’t just the science but the system. One decision can wipe out years of work.
0 · Reply
KarenXue
KarenXue Sep. 3 at 2:50 PM
$REPL dropped after FDA rejected RP1, but the therapy showed real results. Can we support a company that is working to fight cancer?
0 · Reply
MaxPower23
MaxPower23 Sep. 3 at 2:04 PM
$REPL what is this fake meeting about? They have nothing but a meeting date...
0 · Reply
ZenfireTrading
ZenfireTrading Sep. 3 at 1:39 PM
$REPL Lock in your profits, smooth and easy to the long side. If you missed this one and want to see the long/short side of the market come join us at zenfiretrading.com/join 😊👍
0 · Reply